Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.
There is a ban on conducting experiments on real human embryos after 14 days of growth, and researchers at Rockefeller University appear to have found a way to work around that ethical limitation.
Concern about clinical trial transparency, or more accurately the lack of transparency, is an ongoing problem. A new report shows that the lack of transparency also extends to post-marketing commitments that companies agreed to, following regulatory approval of a drug.
GlaxoSmithKline struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California.
Digital Science launched a report on the state of open access monographs. The report addresses the question of how the company integrates and values monographs in the increasingly open digital scholarly network.
Cranbury, N.J.-based Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania are expanding their gene therapy collaboration.
Early detection of cardiovascular disease is becoming possible due to research from Giovanna Guidoboni, Marjorie Skubic and a team at the University of Missouri.
Yale University scientists succeeded in restoring basic cellular activity in pigs’ brains hours after their deaths in a finding that may one day lead to advances in treating human stroke and brain injuries, researchers reported.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
One of the many tricks the AIDS virus, HIV, uses to proliferate so aggressively is it hides from the body’s immune system. Until now, this has largely been a mystery. But researchers with the University Of Montreal, University of Melbourne and others have identified an important mechanism for how HIV plays this disappearing trick.